Grim excavation begins at site believed to contain remains of around 800 babies
Irish officials have begun excavating the grounds of a former home for unwed mothers which authorities say contains the remains of around 800 babies and young children who died there.
"It's a very, very difficult, harrowing story and situation," Irish Prime Minister Micheal Martin said Monday. "We have to wait to see what unfolds now as a result of the excavation."
The former Bon Secours Mother and Baby Home in western Ireland — which closed in 1961 and was run by Catholic nuns — was one of many mother-and-baby homes during the 20th century in the European country. The homes housed unmarried pregnant women as well as tens of thousands of orphans, according to The Associated Press.
Historian Catherine Corless tracked down death certificates in 2014 for nearly 800 children who died at the Bon Secours Mother and Baby Home between the 1920s and 1961. However, she could only find a burial record for one child, the AP reported.
A mass grave was later discovered by investigators in an underground sewage structure at the home. DNA analysis found the structure contained the remains of infants and young children between the ages of 35 weeks gestation and 3 years old, according to the AP.
Family members and survivors will soon have the opportunity to view the works, according to Daniel MacSweeney, who is leading the exhumation of the infant remains.
"This is a unique and incredibly complex excavation," MacSweeney said in a statement.
Any remains recovered from the site will be analyzed and preserved by forensic experts. Identified remains will be returned to family members, while unidentified remains will be buried. The work is expected to take two years to complete, the AP reported.
The sisters who ran the former Bon Secours Mother and Baby Home previously offered a "profound apology," acknowledging they failed to protect the dignity of the women and children that lived there, according to the AP.
In 2021, Prime Minister Martin issued a former state apology after a report found that 9,000 children died in 18 mother-and-baby homes during the 20th century in Ireland.
Daniel MacSweeney and Ireland's National Police and Security Service, An Garda Síochána, did not immediately respond to Fox News Digital's request for comment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Medtronic (MDT) Appoints Dr. Joon Sup Lee to Board of Directors
Medtronic plc (NYSE:MDT) is one of the 11 best European stocks to invest in. On June 23, the company announced the appointment of Dr. Joon Sup Lee as an independent director to its Board of Directors. The appointment went into effect on June 18, 2025. A healthcare specialist in the laboratory testing an Oncology-related product. Dr. Lee's appointment was a result of Medtronic increasing the size of its Board. The new director will serve on the Board's Science and Technology Committee and the Compensation and Talent Committee. Dr. Lee is currently the CEO of Emory Healthcare, Inc., overseeing Georgia's most comprehensive academic health system. Before joining Emory Healthcare, Dr. Lee was the executive director of the University of Pittsburgh Medical Center's (UPMC) Heart and Vascular Institute from 2018 to 2020. He was also a professor of medicine at the University of Pittsburgh School of Medicine. He held various leadership roles at UPMC, including Director of Interventional Cardiology and Director of the Cardiac Catheterization Laboratory. Medtronic plc (NYSE:MDT) is an Irish-domiciled healthcare technology company. It develops and sells medical devices and therapies for chronic conditions across four main segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. Its top products include heart devices, spinal implants, surgical tools, insulin pumps, and neuromodulation systems. Medtronic serves over 79 million patients annually in more than 150 countries. While we acknowledge the potential of MDT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
From Cork to Maidenhead: An Irish nurse's story
A nurse who moved from Ireland to Berkshire in 1948 at the age of 19 to join the newly created National Health Service (NHS) was a "pioneer", her daughter has said. Nora McCarthy was one of thousands of Irish women recruited to train and work in British hospitals after the end of World War Two. Janie Davies said her mother, who died last year aged 95, "absolutely loved" her job as a nurse. Speaking to Radio Berkshire ahead the 77th anniversary of the NHS on 5 July, she said her mother told her it had been "very strict" in the early days. The NHS took control of 480,000 hospital beds in England and Wales in 1948 but it was short of 48,000 nurses so an active recruitment drive was launched in Ireland. At the time, nurse training opportunities in Ireland were limited and expensive, making the chance to train for free in British hospitals with live-in accommodation highly attractive. By the 1960s there were about 30,000 Irish nurses working in the NHS. Ms Davies said her mother saw an advert and decided she wanted to help. Nora first spent a year working at a hospital in Highgate, London, on an orthopaedic ward before an outbreak of tuberculosis (TB), she said. "About summertime 1949, mum and her friend wanted to apply for a job in Maidenhead," she said. "I think working a year on the TB ward was just getting to them, they were seeing a lot of death." Nora spoke fondly of her time in the NHS, said Ms Davies, adding that during the early years she had said it was "very strict" but there was "a lot of camaraderie too". She said her mother had told her of dances at the local church hall which the off-duty nurses would attend and where Nora met her future husband. Ms Davies' daughter Ciara has retraced Nora's journey from Cork to working at Maidenhead General Hospital in Berkshire, as part of her university dissertation. She said: "I started in Ireland, we went to the original green rooms in O'Donovan's where the [nursing] interviews had taken place. "Then to where she caught the bus from in Cork. We saw a little bit of Maidenhead but the original building for Maidenhead General Hospital was no longer there. "There were some surprises about her life that I didn't know, such as learning about tuberculosis and what her life was like on the TB ward." Nora worked as an NHS nurse for 50 years, retiring at the age of 69. Her story has been featured in a book, titled Irish Nurses in the NHS - An Oral History, which explores the life experiences of the Irish migrant nurses. Its co-author Prof Louise Ryan said the NHS described how it was "actively recruiting" in Ireland, with advertisements in national and local papers. NHS recruiters travelled throughout the country and carried out interviews with young women in local hotels. Prof Ryan said: "Their travel was paid, they earned a salary while they trained - plus they got accommodation in the nurses home. "If you can image parents waving their children off on this mammoth journey across the sea to England – knowing there was secure accommodation was very reassuring – they were very well looked after." You can follow BBC Berkshire on Facebook, X (Twitter), or Instagram. Nurses 'proud' to celebrate 40 years of NHS care Nursery nurse congratulated for 45 years of service NHS nurses and healthcare staff offered 5.5% pay rise 'NHS needs fewer managers, more nurses' NHS Irish Nurses in the NHS - An Oral History
Yahoo
2 days ago
- Yahoo
Zollinger Ellison Syndrome Market Analysis Report 2025: Novartis, GSK, Bayer, Pfizer, and Bristol Myers Squibb Dominate
Enhanced treatment options, precision medicine, and advanced diagnostics are fueling growth across major markets Zollinger Ellison Syndrome Market Dublin, June 27, 2025 (GLOBE NEWSWIRE) -- The "Zollinger Ellison Syndrome Market Report and Forecast 2025-2034" report has been added to Zollinger Ellison Syndrome market was valued at USD 1.34 billion in 2024 driven by innovations in treatment options across the 8 major markets. It is expected to grow at a CAGR of 4.40% during the forecast period of 2025-2034 and attain a market value of USD 2.07 billion by 2034. Market growth is driven by the rising awareness of rare disorders, advanced technologies, and improvements in the availability of medicines and surgical treatments. Emphasis on precision medicine and treatment for rare diseases is further fueling the expansion of the in incidence of rare disorders to Drive Market ExpansionThe increasing incidence of rare diseases like Zollinger-Ellison Syndrome is driving market growth. According to the United States Food and Drug Administration's 2024 report, over 7,000 rare diseases affect more than 30 million people in the United States alone. As healthcare accessibility improves and awareness among professionals and patients rises, earlier diagnosis and better management will likely drive demand for specialized treatments, creating significant market opportunities. Based on the treatment, the market is divided into medications, surgery, and cancer therapies. Medications are expected to hold a significant share of the market as they have shown the positive results in controlling the overproduction of acid and symptomatic relief. Proton pump inhibitors and H2 receptor antagonists are the most frequently used drugs, but novel targeted cancer therapies are becoming more popular and are also reshaping the treatment of severe and advanced cases. Based on region, the market is divided into the United States, United Kingdom, Germany, France, Italy, Spain, Japan, and India. The United States holds a substantial share of the market, as it has advanced healthcare infrastructure, high disease awareness, and considerable investments in rare disease research. Access to innovative diagnostic tools and therapies, coupled with a robust pharmaceutical industry, makes it a leader in the advancement of diagnosis and treatment of Zollinger Ellison syndrome. The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:Increased Emphasis on Precision Medicine: The market is witnessing increased adoption of precision medicine approaches, using genetic profiling to identify disease-specific treatments. Personalized medicine strategies are driving better therapeutic outcomes and improved patient satisfaction, fueling innovation, and expanding treatment options tailored to individual Advancements in Diagnostic Technologies to Boost Zollinger Ellison Syndrome Market Value: Emerging diagnostic tools, such as high-resolution imaging and molecular testing, are improving early detection rates for Zollinger Ellison syndrome. These advances improve the accuracy of diagnosis, allowing for timely treatment initiation and contributing to the growth of the market by enabling better patient of Long-Acting Drugs to Enhance Zollinger Ellison Syndrome Market Growth: The introduction of long-acting formulations is another prominent market trend. These drugs guarantee extended symptom control, and enhanced compliance among patients, promoting growth in the pharmacological treatment segment of the of Telemedicine Services to Fuel Zollinger Ellison Syndrome Market Demand: Telemedicine is increasingly being used in the management of Zollinger Ellison syndrome. Patients can reach out for proper specialized care, helping in the improvement of patient engagement, ensuring timely follow-ups, and supporting better disease monitoring, especially in remote or underserved Players in the Zollinger Ellison Syndrome MarketThe key features of the market report comprise patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:Novartis AGNovartis, headquartered in Basel, Switzerland, was established in 1996. Its prominent product, Sandostatin, is widely used in the treatment of Zollinger-Ellison syndrome, among other conditions. This injectable medication, containing octreotide acetate, helps control symptoms and reduce growth hormone levels, often in combination with proton pump inhibitors or H2-antagonist Inc., headquartered in New York City and established in 1849, is a leading pharmaceutical company known for innovative healthcare solutions. Its product, Protonix, which includes Protonix Delayed-Release Pantoprazole Sodium Tablets and Protonix Delayed-Release Pantoprazole Sodium Granules, is used to treat conditions such as Zollinger-Ellison Syndrome. Protonix, a proton pump inhibitor (PPI), is prescribed for pathological hypersecretory conditions, providing critical relief in reducing excessive stomach acid N.V., established in 1961 and headquartered in Hertfordshire, England, is a global pharmaceutical company. It offers a wide range of products, including Lansoprazole delayed-release orally disintegrating tablets (ODT), which are used to treat conditions such as Zollinger-Ellison syndrome. It focuses on providing high-quality medicines International International Inc., established in 1931 and headquartered in Deerfield, Illinois, is a global leader in pharmaceuticals, specializing in injectable products. In December 2024, the company launched Pantoprazole Sodium in 0.9% Sodium Chloride Injection, aimed at treating Zollinger-Ellison Syndrome (ZE). This addition supports their commitment to advancing critical care Questions Answered in the Zollinger Ellison Syndrome Market Report What was the Zollinger Ellison syndrome market value in 2024? What is the Zollinger Ellison syndrome market forecast outlook for 2025-2034? What are the regional markets covered in the report? What is the market segmentation based on treatment? What is the market breakup based on end users? What is the market breakup based on the distribution channels? What major factors aid the Zollinger Ellison syndrome market demand? How has the market performed so far and how is it anticipated to perform in the coming years? What are the major drivers, opportunities, and restraints in the market? What are the major trends influencing the market? Which regional market is expected to dominate the market share in the forecast period? Which country is likely to experience elevated growth during the forecast period? Who are the key players involved in the Zollinger Ellison syndrome market? What are the current unmet needs and challenges in the market? How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics? Key Attributes Report Attribute Details No. of Pages 400 Forecast Period 2025-2034 Estimated Market Value (USD) in 2025 $1.34 Billion Forecasted Market Value (USD) by 2034 $2.07 Billion Compound Annual Growth Rate 4.4% Regions Covered Global Key Topics Covered1 Preface1.1 Objectives of the Study1.2 Key Assumptions1.3 Report Coverage - Key Segmentation and Scope1.4 Research Methodology2 Executive Summary3 Zollinger Ellison Syndrome Market Overview - 8 Major Markets3.1 Zollinger Ellison Syndrome Market Historical Value (2018-2024)3.2 Zollinger Ellison Syndrome Market Forecast Value (2025-2034)4 Vendor Positioning Analysis4.1 Key Vendors4.2 Prospective Leaders4.3 Niche Leaders4.4 Disruptors5 Zollinger Ellison Syndrome Overview5.1 Guidelines and Stages5.2 Pathophysiology5.3 Screening and Diagnosis5.4 Treatment Pathway6 Patient Profile6.1 Patient Profile Overview6.2 Patient Psychology and Emotional Impact Factors6.3 Risk Assessment and Treatment Success Rate7 Zollinger Ellison Syndrome Market - Epidemiology Scenario and Forecast - 8 Major Markets7.1 8MM Epidemiology Scenario Overview (2018-2034)7.2 Prevalence, by Country7.3 Diagnosed Cases, by Country7.4 Treatment Seeking Rate, by Country8 Zollinger Ellison Syndrome Market Landscape - 8 Major Markets8.1 Zollinger Ellison Syndrome Market: Developers Landscape8.1.1 Analysis by Year of Establishment8.1.2 Analysis by Company Size8.1.3 Analysis by Region8.2 Zollinger Ellison Syndrome Market: Product Landscape8.2.1 Analysis by Treatment Type9 Zollinger Ellison Syndrome Market Challenges and Unmet Needs9.1 Treatment Pathway Challenges9.2 Compliance and Drop-Out Analysis9.3 Awareness and Prevention Gaps10 Cost of Treatment11 Zollinger Ellison Syndrome Market Dynamics11.1 Market Drivers and Constraints11.2 SWOT Analysis11.2.1 Strengths11.2.2 Weaknesses11.2.3 Opportunities11.2.4 Threats11.3 PESTEL Analysis11.3.1 Political11.3.2 Economic11.3.3 Social11.3.4 Technological11.3.5 Legal11.3.6 Environment11.4 Porter's Five Forces Model11.4.1 Bargaining Power of Suppliers11.4.2 Bargaining Power of Buyers11.4.3 Threat of New Entrants11.4.4 Threat of Substitutes11.4.5 Degree of Rivalry11.5 Key Demand Indicators11.6 Key Price Indicators11.7 Industry Events, Initiatives, and Trends11.8 Value Chain Analysis12 Zollinger Ellison Syndrome Market Segmentation (218-2034) - 8 Major Markets12.1 Zollinger Ellison Syndrome Market (2018-2034) by Treatment12.2 Zollinger Ellison Syndrome Market (2018-2034) by Distribution Channel12.3 Zollinger Ellison Syndrome Market (2018-2034) by End User12.4 Zollinger Ellison Syndrome Market (2018-2034) by Region 13 United States Zollinger Ellison Syndrome Market (218-2034) 14 United Kingdom Zollinger Ellison Syndrome Market (218-2034) 15 Germany Zollinger Ellison Syndrome Market (218-2034) 16 France Zollinger Ellison Syndrome Market (218-2034) 17 Italy Zollinger Ellison Syndrome Market (218-2034) 18 Spain Zollinger Ellison Syndrome Market (218-2034) 19 Japan Zollinger Ellison Syndrome Market (218-2034) 20 India Zollinger Ellison Syndrome Market (218-2034) 21 Regulatory Framework21.1 Regulatory Overview21.2 US FDA21.3 EU EMA21.4 Japan PMDA21.5 India CDSCO21.6 Others 22 Patent Analysis22.1 Analysis by Type of Patent22.2 Analysis by Publication Year22.3 Analysis by Issuing Authority22.4 Analysis by Patent Age22.5 Analysis by CPC Analysis22.6 Analysis by Patent Valuation 23 Clinical Trials Analysis23.1 Analysis by Trial Registration Year23.2 Analysis by Trial Status23.3 Analysis by Trial Phase23.4 Analysis by Therapeutic Area23.5 Analysis by Geography 24 Grants Analysis24.1 Analysis by Year24.2 Analysis by Amount Awarded24.3 Analysis by Issuing Authority24.4 Analysis by Grant Application24.5 Analysis by Funding Institute24.6 Analysis by NIH Departments24.7 Analysis by Recipient Organization 25 Funding and Investment Analysis25.1 Analysis by Funding Instances25.2 Analysis by Drug Class of Funding25.3 Analysis by Funding Amount25.4 Analysis by Leading Players25.5 Analysis by Leading Investors25.6 Analysis by Geography 26 Strategic Initiatives26.1 Analysis by Partnership Instances26.2 Analysis by Drug Class of Partnership26.3 Analysis by Leading Players26.4 Analysis by Geography 27 Supplier Landscape27.1 Market Share Analysis, By Region (Top 5 Companies)27.2 Novartis AG27.3 GSK PLC27.4 Bayer AG27.5 Pfizer Inc.27.6 Bristol Myers Squibb Company27.7 Mylan N.V.27.8 Teva Pharmaceutical Industries Ltd.27.9 Johnson & Johnson Services, Inc.27.10 Lupin Limited27.11 Alembic Pharmaceuticals Limited27.12 Baxter International Inc. 28 Zollinger Ellison Syndrome Market - Distribution Model (Additional Insight)28.1 Overview28.2 Potential Distributors28.3 Key Parameters for Distribution Partner Assessment29 Key Opinion Leaders (KOL) Insights (Additional Insight)30 Payment Methods (Additional Insight)30.1 Government Funded30.2 Private Insurance30.3 Out-of-PocketFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Zollinger Ellison Syndrome Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
